Recent Quotes (30 days)

You have no recent quotes
chg | %

Valeant Pharmaceuticals Intl Inc  

(Public, TSE:VRX)   Watch this stock  
Find more results for VRX
124.54
+0.44 (0.35%)
Aug 21 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 123.32 - 125.09
52 week 99.90 - 170.45
Open 123.48
Vol / Avg. 137,688.00/353,729.00
Mkt cap 41.64B
P/E     -
Div/yield     -
EPS -2.46
Shares 333.78M
Beta 0.44
Inst. own 85%
Oct 29, 2014
Q3 2014 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 31, 2014
Q2 2014 Valeant Pharmaceuticals International, Inc. Earnings Release
Jul 31, 2014
Q2 2014 Valeant Pharmaceuticals International Inc Earnings Call
Jun 17, 2014
Valeant Pharmaceuticals International Inc Conference Call to Correct Recent Misrepresentations
Jun 2, 2014
Valeant Pharmaceuticals International, Inc. Conference Call to Discuss Revised Offer for Allergan
May 28, 2014
Valeant Pharmaceuticals International, Inc. at Sanford C Bernstein Strategic Decisions Conference
May 28, 2014
Valeant Pharmaceuticals International, Inc. Investor Meeting to Discuss the Merger Proposal with Allergan Conference Call
  

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 5.98% -14.97%
Operating margin 17.40% -8.22%
EBITD margin - 51.28%
Return on average assets 1.75% -3.76%
Return on average equity 9.75% -19.60%
Employees 17,200 -
CDP Score - -

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

Description

Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. In June 2014, Akorn Inc sold its subsidiary, ECR Pharmaceuticals (ECR) to Valeant Pharmaceuticals International, Inc. In July 2014, the Company acquired PreCision Dermatology, Inc.

Officers and directors

J. Michael Michael Pearson Chairman of the Board, Chief Executive Officer
Age: 53
Bhaskar Chaudhuri Ph.D. President
Age: 59
Howard Bradley Schiller Chief Financial Officer, Executive Vice President, Director
Peter J. Blott Chief Financial Officer, Executive Vice President
Age: 50
Elisa A. Karlson Executive Vice President, Chief Administrative Officer
Age: 53
Robert Roswell Chai-Onn Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development
Age: 42
Steve T. Min Executive Vice President, General Counsel, Corporate Secretary
Age: 50
Ari Kellen Executive Vice President, Company Group Chairman
Laizer D. Kornwasser Executive Vice President, Company Group Chairman
Martin N Mercer Executive VP, International